BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

249 related articles for article (PubMed ID: 31505095)

  • 1. Hepatitis B virus reactivation during belatacept treatment after kidney transplantation.
    Cambier ML; Canestri A; Lependeven C; Peltier J; Mesnard L; Dahan K
    Transpl Infect Dis; 2019 Dec; 21(6):e13170. PubMed ID: 31505095
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Reactivation of occult hepatitis B virus infection under treatment with abatacept: a case report.
    Talotta R; Atzeni F; Sarzi Puttini P
    BMC Pharmacol Toxicol; 2016 Apr; 17():17. PubMed ID: 27098382
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Rituximab and hepatitis B reactivation in HBsAg-negative/ anti-HBc-positive kidney transplant recipients.
    Lee J; Park JY; Huh KH; Kim BS; Kim MS; Kim SI; Ahn SH; Kim YS
    Nephrol Dial Transplant; 2017 Apr; 32(4):722-729. PubMed ID: 28339910
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Risk of hepatitis B reactivation in hepatitis B surface antigen seronegative and core antibody seropositive kidney transplant recipients.
    Querido S; Weigert A; Adragão T; Rodrigues L; Jorge C; Bruges M; Machado D
    Transpl Infect Dis; 2019 Feb; 21(1):e13009. PubMed ID: 30295412
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Outcomes and risk factors for hepatitis B virus (HBV) reactivation after kidney transplantation in occult HBV carriers.
    Chen GD; Gu JL; Qiu J; Chen LZ
    Transpl Infect Dis; 2013 Jun; 15(3):300-5. PubMed ID: 23473005
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Hepatitis B virus reactivation among hepatitis C patients treated with direct-acting antiviral therapies in routine clinical practice.
    Loggi E; Gitto S; Galli S; Minichiello M; Conti F; Grandini E; Scuteri A; Vitale G; Di Donato R; Cursaro C; Furlini G; Andreone P
    J Clin Virol; 2017 Aug; 93():66-70. PubMed ID: 28654775
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Kinetics of viral loads and risk of hepatitis B virus reactivation in hepatitis B core antibody-positive rheumatoid arthritis patients undergoing anti-tumour necrosis factor alpha therapy.
    Lan JL; Chen YM; Hsieh TY; Chen YH; Hsieh CW; Chen DY; Yang SS
    Ann Rheum Dis; 2011 Oct; 70(10):1719-25. PubMed ID: 21719446
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Entecavir versus lamivudine for hepatitis B prophylaxis in patients with haematological disease.
    Chen FW; Coyle L; Jones BE; Pattullo V
    Liver Int; 2013 Sep; 33(8):1203-10. PubMed ID: 23522150
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Hepatitis B virus reactivation in kidney transplant patients with resolved hepatitis B virus infection: Risk factors and the safety and efficacy of preemptive therapy.
    Mei T; Noguchi H; Hisadome Y; Kaku K; Nishiki T; Okabe Y; Nakamura M
    Transpl Infect Dis; 2020 Apr; 22(2):e13234. PubMed ID: 31856328
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Reactivation of hepatitis B virus infection in patients with hemo-lymphoproliferative diseases, and its prevention.
    Sagnelli C; Pisaturo M; Calò F; Martini S; Sagnelli E; Coppola N
    World J Gastroenterol; 2019 Jul; 25(26):3299-3312. PubMed ID: 31341357
    [TBL] [Abstract][Full Text] [Related]  

  • 11. High titers of anti-HBs prevent rituximab-related viral reactivation in resolved hepatitis B patient with non-Hodgkin's lymphoma.
    Cho Y; Yu SJ; Cho EJ; Lee JH; Kim TM; Heo DS; Kim YJ; Yoon JH
    J Med Virol; 2016 Jun; 88(6):1010-7. PubMed ID: 26531242
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Hepatitis B virus reactivation in patients with resolved hepatitis B virus infection receiving chemotherapy or immunosuppressive therapy.
    Su YC; Lin PC; Yu HC; Wu CC
    Eur J Gastroenterol Hepatol; 2018 Aug; 30(8):925-929. PubMed ID: 29621049
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A Hospital-Based Analysis in the Department of Clinical Chemistry for the Patients with HBV Reactivation after Anti-Cancer or Immunosuppressive Therapy.
    Matsuzaki T; Ohkubo K; Yuki M; Kawashima H; Matsunaga A
    Rinsho Byori; 2015 Mar; 63(3):297-304. PubMed ID: 26524851
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Hepatitis B virus reactivation and efficacy of prophylaxis with lamivudine in patients undergoing allogeneic stem cell transplantation.
    Giaccone L; Festuccia M; Marengo A; Resta I; Sorasio R; Pittaluga F; Fiore F; Boccadoro M; Rizzetto M; Bruno B; Marzano A
    Biol Blood Marrow Transplant; 2010 Jun; 16(6):809-17. PubMed ID: 20060484
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The difficulties of managing severe hepatitis B virus reactivation.
    Roche B; Samuel D
    Liver Int; 2011 Jan; 31 Suppl 1():104-10. PubMed ID: 21205146
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Hepatitis B reactivation in HBsAg-negative/HBcAb-positive patients receiving immunosuppressive therapy for glomerulonephritis: a retrospective analysis.
    Fang J; Li W; Peng X; Tan Z; Tan M; Zhang C; Wang W; Xu Z; Zhou G
    Int Urol Nephrol; 2017 Mar; 49(3):475-482. PubMed ID: 28032257
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prophylactic antiviral therapy in allogeneic hematopoietic stem cell transplantation in hepatitis B virus patients.
    Liao YP; Jiang JL; Zou WY; Xu DR; Li J
    World J Gastroenterol; 2015 Apr; 21(14):4284-92. PubMed ID: 25892880
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Fatal reactivation of hepatitis B virus in a patient who was hepatitis B surface antigen negative and core antibody positive before receiving chemotherapy for non-Hodgkin lymphoma.
    Wu JM; Huang YH; Lee PC; Lin HC; Lee SD
    J Clin Gastroenterol; 2009; 43(5):496-8. PubMed ID: 19247200
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A snapshot of virological presentation and outcome of immunosuppression-driven HBV reactivation from real clinical practice: Evidence of a relevant risk of death and evolution from silent to chronic infection.
    Salpini R; Battisti A; Colagrossi L; Di Carlo D; Fabeni L; Piermatteo L; Cerva C; Lichtner M; Mastroianni C; Marignani M; Maylin S; Delaugerre C; Morisco F; Coppola N; Marrone A; Angelico M; Sarmati L; Andreoni M; Perno CF; Ceccherini-Silberstein F; Svicher V
    J Viral Hepat; 2019 Jul; 26(7):846-855. PubMed ID: 30974483
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Adefovir is effective to promote development of immunity to donor origin hepatitis B virus in an allogeneic transplant recipient: a case report.
    Yaşar DG; Suyanı E; Özenirler S; Sucak GT
    Transplant Proc; 2013 Mar; 45(2):833-4. PubMed ID: 23498831
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.